Session » Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Date: Saturday, November 16, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0760

A Macrophage-smooth Muscle Cell Axis Influences Vascular Remodeling Through Activation of the EGFR Pathway in Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0768

Addressing Gaps in Polymyalgia Rheumatica: A Systematic Literature Review

10:30AM-12:30PM: Abstract Number: 0749

Age at Disease Onset Influences the Clinical Phenotype and Outcome of Patients with Takayasu Arteritis: Results from a Monocentric Cohort of 167 Patients

10:30AM-12:30PM: Abstract Number: 0761

An Observational Study of Lifetime Prevalence of Thromboembolism Among Patients with Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0769

Baseline Evaluation of Diagnoses and Prescribing Patterns in Polymyalgia Rheumatica

10:30AM-12:30PM: Abstract Number: 0744

Cerebrovascular Accidents (CVA) in Giant Cell Arteritis: Identification of Predictive Factors from the ARTESER Registry

10:30AM-12:30PM: Abstract Number: 0755

Characteristics Associated with Long-Term Glucocorticoids Use in Patients with New Onset Polymyalgia Rheumatica

10:30AM-12:30PM: Abstract Number: 0754

Clinical Characterization of Aortitis and Periaortitis in a Cohort of 134 Patients from a Single Universitary Center. A Model-based Cluster Analysis

10:30AM-12:30PM: Abstract Number: 0747

Clofutriben to Improve the Benefit-Risk Profile of Prednisolone in Patients with Polymyalgia Rheumatica

10:30AM-12:30PM: Abstract Number: 0767

Comparing Large Vessel Uptake of 68Ga-HA-DOTATATE to 18F-FDG Using PET/CT Imaging in Patients with Active Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0750

Corticosteroid Withdrawal Using Tocilizumab and Its Association with Autoantibody Profile in Takayasu Arteritis: A Multicenter, Single-arm, Prospective Study

10:30AM-12:30PM: Abstract Number: 0762

Different Giant Cell Arteritis Phenotypes May Present Distinct Types of Ischemic Complications

10:30AM-12:30PM: Abstract Number: 0758

Difficult to Treat Takayasu Arteritis: Comparative Efficacy of Colchicine and Tofacitinib

10:30AM-12:30PM: Abstract Number: 0756

Effectiveness and Safety of Tocilizumab in the Treatment of Polymyalgia Rheumatica: A Meta-Analysis

10:30AM-12:30PM: Abstract Number: 0748

Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica

10:30AM-12:30PM: Abstract Number: 0740

Evaluation of an Accelerated Physical Aging Phenotype in Newly Diagnosed Patients with Polymyalgia Rheumatica

10:30AM-12:30PM: Abstract Number: 0743

Higher Baseline FDG Musculoskeletal Uptake at PET/CT Is Associated with a Higher Remission Rate in Polymyalgia Rheumatica: A Retrospective 3-year Observational Study

10:30AM-12:30PM: Abstract Number: 0759

Macrophage-Lineage Cells in Giant Cell Arteritis Express MMP12, Phagocytosis and Osteoclast-associated Molecules That May Contribute to Destruction of the Tunica Media

10:30AM-12:30PM: Abstract Number: 0766

Neutrophil Transcriptomics in VEXAS Syndrome

10:30AM-12:30PM: Abstract Number: 0752

Non-classical Organ Involvement in Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0739

One Year Outcomes in Those with Isolated PMR Recruited via a Fast Track PMR Clinic

10:30AM-12:30PM: Abstract Number: 0764

Primary Treatment Failure to Tocilizumab in Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0738

Quantitative Vascular US Has Additional Diagnostic and Prognostic Value in GCA

10:30AM-12:30PM: Abstract Number: 0757

Regulation of Macrophage Differentiation by Serum Adiponectin: A Novel Mechanism to Increase Alternatively Activated Macrophages During the Remission Phase of Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0737

Rurality and Delayed Diagnosis of Giant Cell Arteritis – a Single Center Experience

10:30AM-12:30PM: Abstract Number: 0741

Serum Markers of Disease Activity in Polymyalgia Rheumatica

10:30AM-12:30PM: Abstract Number: 0746

Single-cell RNA-Seq Analysis Reveals Distinct Compositional Characterizations and Transcriptomic Profiles of Macrophages in Takayasu’s Arteritis

10:30AM-12:30PM: Abstract Number: 0751

Sustained Drug-free Remission in Giant Cell Arteritis: Results Results of the Spanish ARTESER Registry

10:30AM-12:30PM: Abstract Number: 0765

Tocilizumab in Extracranial Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: A Multicentric Observational Comparative Study

10:30AM-12:30PM: Abstract Number: 0745

Tocilizumab in Monotherapy vs. Combined in Aortitis Associated with Giant Cell Arteritis. Multicenter Open-label Study of 196 Patients

10:30AM-12:30PM: Abstract Number: 0763

Transcriptional Analysis of Both Normal and Abnormal TABs in Biopsy-proven GCA Reveals a Shared Gene Expression Profile Compared to Clinically Diverse Controls

10:30AM-12:30PM: Abstract Number: 0753

Treatment and Evolution in 134 Patients with Aortitis and Periaortitis. Experience of a Single Referral Centre

10:30AM-12:30PM: Abstract Number: 0736

Treatment of IgG4-Related Disease (IgG4-RD) with Elotuzumab, an Inhibitor of SLAM-F7: Report of a Phase 2 Clinical Trial

10:30AM-12:30PM: Abstract Number: 0742

Use of FDG-PET to Monitor Disease Activity in Patients with Giant Cell Arteritis on Tocilizumab

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].